Introduction {#s1}
============

Laminins, αβγ trimeric glycoproteins, are major components of basement membranes (BMs) that play crucial roles in transmitting BM signals to cells. Various cellular processes including adhesion, migration, survival, proliferation, and differentiation are supported by laminins through interactions with cell-surface receptors. The most important receptors for sensing laminin signals are integrins, which are αβ dimeric cell-surface transmembrane proteins.

There are several modes of laminin--integrin interactions. One of the integrin-binding sites in laminins is located in a C-terminal αβγ complex known as the E8 fragment ([@bib35]). The E8 fragments of laminins interact with multiple integrins, including α3β1, α6β1, α6β4, and α7β1 ([@bib35]; [@bib12]; [@bib41]). It is known that αβγ trimer formation, LG1--3 domains of the α chain, and Glu residue in the γ1 chain C-terminal tail (γ1C-Glu) ([Fig 1A](#fig1){ref-type="fig"}) are prerequisites for the integrin-binding ability of E8 fragments ([@bib36]; [@bib9], [@bib12]; [@bib42]). Recently, the crystal structures of truncated E8 fragments derived from laminin-111 and laminin-511 were solved ([@bib29]; [@bib40]). The structures predicted that γ1C-Glu can bind directly to the metal ion-dependent adhesion site in the integrin β1 subunit. Thus, the biochemical significance of γ1C-Glu for integrin binding is apparent, but its physiological roles remain to be fully addressed.

![Binding of recombinant laminin-111, laminin-511, and their EQ mutants to integrins.\
**(A)** Schematic diagram of a full-length laminin. The Glu (E) residue in the C-terminal region of the γ1 chain critical for integrin binding is indicated. **(B--L)** Binding of recombinant integrin α1β1 (B), α2β1 (C), α3β1 (D), α6β1 (E), α6β4 (F), α7x1β1 (G), α7x2β1 (H), α9β1 (I), αvβ3 (J), αvβ5 (K), and α5β1 (L) to immobilized laminins (LMs), type-I and type-IV collagens, polydom, and vitronectin. **(M)** Anti-FLAG antibody binding for quantification of immobilized recombinant proteins. Vertical axes represent absorbance at 490 nm which indicates integrin binding. Data represent means ± SD of triplicate assays.](LSA-2018-00064_Fig1){#fig1}

Here, we investigated the physiological significance of γ1C-Glu for laminin--integrin interactions in vivo by generating a knock-in mouse strain in which γ1C-Glu was substituted with Gln. The resulting knock-in mice showed early postimplantation lethality, underscoring the critical role of γ1C-Glu--dependent laminin--integrin interactions for early embryonic development. Based on these findings, we established another knock-in mouse strain in which the γ1C Glu to Gln (EQ) mutation can be introduced on demand by the Cre-loxP system.

Results and Discussion {#s2}
======================

γ1 EQ mutation specifically abolishes laminin binding to α3, α6, and α7 integrins in vitro {#s3}
------------------------------------------------------------------------------------------

Before starting in vivo studies, we confirmed the impact of γ1C-Glu on integrin binding by laminins in vitro ([Fig 1](#fig1){ref-type="fig"}). For this, we expressed and purified recombinant full-length laminin-111 and laminin-511 and their derivatives containing the EQ mutation ([Fig S1](#figS1){ref-type="fig"}). Because a panel of integrins including α1β1, α2β1, α3β1, α6β1, α6β4, α7β1, α9β1, αvβ3, and αvβ5 were reported to interact with these laminins ([@bib6]; [@bib28]; [@bib31]; [@bib26]), we expressed these integrins as truncated soluble forms in mammalian cells. Integrin α5β1 was also included as a negative control. The recombinant integrins were assessed for their abilities to bind to the laminins and their EQ mutants by solid-phase binding assays ([@bib12]) ([Figs 1B--M](#fig1){ref-type="fig"} and [S2A](#figS2){ref-type="fig"}).

![Recombinant laminins used for in vitro binding assay.\
**(A)** Coomassie Brilliant Blue staining of affinity-purified recombinant laminin-111, laminin-511, and their EQ mutants. SDS--PAGE was carried out in 4% polyacrylamide gels under reducing conditions. **(B)** Western blot analyses of purified recombinant laminin-111, laminin-511, and their EQ mutants with mAbs against α1, α5, β1, and γ1 subunits to confirm the authenticity of the purified laminin isoforms.](LSA-2018-00064_FigS1){#figS1}

![Binding of recombinant laminin-111, laminin-511, and their EQ mutants to integrins.\
**(A)** Binding of recombinant integrin α5β1 to immobilized laminins, type I and IV collagens, polydom, vitronectin, and fibronectin included as a positive control ligand for integrin α5β1 to verify recombinant integrin α5β1 activity. **(B)** Binding of recombinant integrin α6β1 to immobilized human laminin-111 (LM111), its EQ mutant, and mouse laminin-111 purified from Engelbreth-Holm-Swarm tumor (EHS-LM) under increasing coating concentrations (5, 25, and 100 nM). Vertical axes represent absorbance at 490 nm, which indicates integrin binding. Data represent means ± SD of triplicate assays.](LSA-2018-00064_FigS2){#figS2}

Integrins α3β1, α6β1, α6β4, and α7x1β1 bound specifically to laminin-511, whereas integrin α7x2β1 bound to both laminin-111 and laminin-511 ([Fig 1D--H](#fig1){ref-type="fig"}). Integrin α6β1 binding to recombinant laminin-111 was weak under the used condition ([Fig 1E](#fig1){ref-type="fig"}), unlike in previous reports that used Engelbreth-Holm-Swarm (EHS) tumor-derived mouse laminin-111 ([@bib35]; [@bib25], [@bib26]). When the coating concentration of laminin-111 was increased, integrin α6β1 was capable of binding to both mouse and human laminin-111 in a dose-dependent manner, but mouse laminin-111 had significantly more affinity than human recombinant laminin-111 for integrin α6β1 ([Fig S2B](#figS2){ref-type="fig"}). Introduction of the γ1 EQ mutation abolished the abilities of laminin-111 and laminin-511 to bind to these integrins, consistent with our previous reports ([@bib12]; [@bib41]). Among the other integrins examined, two Arg-Gly-Asp (RGD)-binding integrins, αvβ3 and αvβ5, exhibited significant binding to laminin-511 and weaker binding to laminin-111, and this binding was not compromised by the γ1 EQ mutation ([Fig 1J and K](#fig1){ref-type="fig"}). No binding to integrins α1β1, α2β1, α9β1, and α5β1 was observed ([Figs 1B, C, I, L](#fig1){ref-type="fig"} and [S2A](#figS2){ref-type="fig"}). This comprehensive survey of the integrin-binding activities of full-length laminin-111 and laminin-511 and their EQ mutants clearly showed that γ1 laminins were susceptible to the γ1 EQ mutation for their interactions with classical laminin-binding integrins, that is, α3β1, α6β1, α6β4, and α7β1.

Generation of *Lamc1*^EQ^ mice and embryonic lethality {#s4}
------------------------------------------------------

To evaluate the impact of the γ1 EQ mutation in vivo, we generated a γ1 EQ knock-in allele, *Lamc1*^*EQ*^, in which the codon encoding γ1C-Glu was mutated to introduce Gln ([Fig 2A and B](#fig2){ref-type="fig"}). Although *Lamc1*^*EQ*/+^ heterozygous mice were fertile and did not exhibit any developmental defects, no *Lamc1*^*EQ*/*EQ*^ neonates were obtained ([Fig 2C](#fig2){ref-type="fig"}).

![Generation of *Lamc1*^EQ/EQ^ knock-in mice.\
**(A)** Schematic diagram of the targeted mutation of *Lamc1*. The open boxes represent exons. The knock-in construct was designed to replace WT exon 28 encoding Glu at residue 1,605 with a mutant exon 28 encoding Gln at residue 1,605. The probes used for Southern blotting are indicated by bold lines. **(B)** Southern blot analyses of genomic DNA from WT, *Lamc1*^*EQ(neo)*/+^, and *Lamc1*^*EQ*/+^ offspring after digestion with SexAI and PacI. The detection of 9.0- and 7.4-kbp fragments with probe 1 and probe 2, respectively, in the *Lamc1*^*EQ(neo)*/+^ lanes indicates the occurrence of the expected homologous recombination. The detection of a 7.4-kbp fragment with probe 1 in the *Lamc1*^*EQ*/+^ lane indicates that the neomycin-resistance gene has been removed from the *Lamc1*^*EQ(neo)*^ allele by the Cre-loxP system. **(C)** Survival of WT, *Lamc1*^*EQ*/+^, and *Lamc1*^*EQ*/*EQ*^ littermates obtained from *Lamc1*^*EQ*/+^ intercrosses. **(D)** Western analyses of a protein extract from a *Lamc1*^*EQ*/*EQ*^ E7.5 whole embryo and Matrigel using an anti-laminin antibody under nonreducing conditions. **(E, F)** In situ binding of recombinant integrin α7x2β1 (green) in E7.5 WT or *Lamc1*^*EQ*/+^ (E) and *Lamc1*^*EQ*/*EQ*^ (F) frozen sections. The RM was counterstained with an anti--laminin-α1 mAb (magenta). Bars, 100 μm. **(G, H)** Light microscopic images of control *Lamc1*^*EQ*/+^ (G) and *Lamc1*^*EQ*/*EQ*^ (H) E7.5 whole embryos. The filled arrowhead indicates the PYS. The open arrowheads indicate trophoblast giant cells. Bars, 200 μm. **(I--K)** Immunofluorescence staining for cytokeratin-8 (magenta) and laminin (green) in WT or *Lamc1*^*EQ*/+^ (I) and *Lamc1*^*EQ*/*EQ*^ (J, K) E7.5 sections. Blue, nuclei. The boxed area in J is magnified in K. The open diamonds in I indicate the blood sinus. The asterisks in I and J indicate trophoblast giant cells. The arrowheads in K indicate the extracellular matrix structure. Bars, 100 μm. Amn, amnion; Ch, chorion; ExE, extraembryonic ectoderm; Epi, epiblast; S, SexAI restriction site; P, PacI restriction site; TK, thymidine kinase gene; EPC, ectoplacental cone; EC, egg cylinder; PYS, parietal yolk sac.](LSA-2018-00064_Fig2){#fig2}

Because αβγ trimer formation is a prerequisite for efficient secretion of laminins ([@bib44]), we examined whether laminins formed αβγ trimers in *Lamc1*^*EQ*/*EQ*^ mice. Protein extracts from *Lamc1*^*EQ*/*EQ*^ E7.5 embryos were subjected to SDS--PAGE under nonreducing conditions and immunoblotted with an anti-laminin antibody. *Lamc1*^*EQ*/*EQ*^ embryonic extracts produced a signal at ∼800 kD similar to the case for Matrigel, a laminin-111--rich mouse tumor extract ([Fig 2D](#fig2){ref-type="fig"}). These results confirmed that EQ mutant laminins were able to form αβγ trimers. To address whether both laminin-111 and laminin-511 with a mutated γ1 chain can be secreted normally, we expressed these laminins in human 293 cells, and conditioned media were subjected to SDS--PAGE under non-reducing conditions and subsequent immunoblotting. No significant difference was detected in the amounts of the secreted heterotrimers between laminin-111/-511 and their EQ-mutants ([Fig S3](#figS3){ref-type="fig"}), suggesting that laminin-111 and laminin-511 with the mutated γ1 chain were secreted normally. Therefore, *Lamc1*^*EQ*/*EQ*^ mice were phenotypically different from *Lamc1*^−/−^ mice ([@bib34]), because they expressed αβγ trimeric laminin, whereas *Lamc1*^−/−^ mice did not. When E7.5 embryo sections were examined for binding of integrin α7x2β1, which can bind both laminin-111 and laminin-511 ([Fig 1H](#fig1){ref-type="fig"}), WT and *Lamc1*^*EQ*/+^ embryos showed specific integrin α7x2β1 binding in their laminin-positive BMs ([Fig 2E](#fig2){ref-type="fig"}). *Lamc1*^*EQ*/*EQ*^ homozygotes were distinguished from the other embryos by the absence of this integrin binding ([Fig 2F](#fig2){ref-type="fig"}). These results demonstrated that the γ1C-Glu--dependent integrin-binding activity of laminins was abolished by the γ1 EQ mutation in vivo.

![Secretion efficiency of recombinant laminin-111, laminin-511, and their EQ mutants.\
SDS--PAGE under nonreducing conditions and subsequent immunoblot analyses of the conditioned media of human 293 cells transiently expressing laminin-111, laminin-511, or their EQ mutants. The anti--laminin-γ1 antibody detected secreted heterotrimeric laminins at around 800 kDa (arrowheads). Asterisks refer to the β1-γ1 dimer band. Conditioned medium of cells transfected with empty vectors (Mock) was also analyzed as a control.](LSA-2018-00064_FigS3){#figS3}

To address the embryonic lethality of *Lamc1*^*EQ*/*EQ*^ mice, E7.5 egg cylinders were investigated morphologically by light microscopy or sectioned and examined by immunofluorescence. Because laminin-111 and laminin-511 are expressed in Reichert\'s membrane (RM) ([@bib30]; [@bib24]), the parietal yolk sac, an extraembryonic tissue enveloping the egg cylinder, was visualized by its laminin-positive BM in sections of control WT/*Lamc1*^*EQ*/+^ embryos ([Fig 2G and I](#fig2){ref-type="fig"}). However, a parietal sac was not observed in *Lamc1*^*EQ*/*EQ*^ homozygotes, although laminin was expressed ([Fig 2H, J, and K](#fig2){ref-type="fig"}). Trophoblast giant cells, which are cytokeratin-8--positive and have large nuclei, were recognized in both WT/*Lamc1*^*EQ*/+^ and *Lamc1*^*EQ*/*EQ*^ embryos ([Fig 2I and J](#fig2){ref-type="fig"}), suggesting that extraembryonic cell differentiation was not affected in *Lamc1*^*EQ*/*EQ*^ homozygotes. Collectively, *Lamc1*^*EQ*/*EQ*^ mice showed morphogenetic defects at the early postimplantation stage.

γ1C-Glu--dependent integrin binding is dispensable for BM deposition {#s5}
--------------------------------------------------------------------

To determine the timing for the morphological abnormality in *Lamc1*^*EQ*/*EQ*^ homozygotes, we investigated the development of preimplantation embryos. Before implantation (E4.0 and E4.3), formation of the blastocoel cavity and inner cell mass were comparable between WT and *Lamc1*^*EQ*/*EQ*^ blastocysts ([Fig 3A--H](#fig3){ref-type="fig"}). At E4.0, laminins were barely detected at the basal surface of the mural trophectoderm in blastocysts, irrespective of the genotypes ([Fig 3A--D](#fig3){ref-type="fig"}). Similarly, perlecan, another BM component, was not detected in E4.0 blastocysts ([Fig 3A and B](#fig3){ref-type="fig"}). In E4.3 blastocysts, laminins were detected at the basal surface of the mural trophectoderm in both WT and *Lamc1*^*EQ*/*EQ*^ blastocysts ([Fig 3E--H](#fig3){ref-type="fig"}). Perlecan was also detected at the basal aspect of the mural trophectoderm in E4.3 blastocysts ([Fig 3E and F](#fig3){ref-type="fig"}). Primitive endoderm cells, the main laminin-producing cells producing dense signals with an anti-laminin antibody, were recognized in both WT and *Lamc1*^*EQ*/*EQ*^ blastocysts (asterisks in [Fig 3E--H](#fig3){ref-type="fig"}). The laminin-binding integrin α6 was localized at the basal surface of the mural trophectoderm in WT and *Lamc1*^*EQ*/*EQ*^ blastocysts irrespective of the laminin deposition in E4.0 ([Fig 3C and D](#fig3){ref-type="fig"}) and E4.3 ([Fig 3G and H](#fig3){ref-type="fig"}) blastocysts. To further examine the BM development in blastocysts, E3.5 blastocysts were flushed out from the uterus and cultured ex vivo for 48 h. In both ex vivo-cultured *Lamc1*^*EQ*/+^ and *Lamc1*^*EQ*/*EQ*^ blastocysts, laminins were densely deposited at the basal surface of the mural trophectoderm, where another BM component, perlecan, was colocalized ([Fig 3I and J](#fig3){ref-type="fig"}). These findings indicate that the preimplantation development of *Lamc1*^*EQ*/*EQ*^ embryos was normal according to their morphology, laminin deposition, and BM formation. It has been reported that deficiency of BM formation in embryoid bodies derived from β1 integrin-null mouse embryonic stem (ES) cells ([@bib2]; [@bib22]) can be rescued by exogenous addition of laminin-111 in vitro ([@bib22]). Because the BM assembly rescued by exogenous laminin-111 was blocked by the addition of the E3 fragment of laminin-111, but not the E8 fragment, E3-binding non-integrin receptors (e.g., dystroglycan, syndecan, and sulfated glycolipids) play dominant roles in the BM assembly of laminins. The dispensability of integrin binding of laminins in BM formation shown here using ex vivo-cultured *Lamc1*^EQ/EQ^ blastocysts is consistent with these previous findings. Nevertheless, we cannot exclude the possibility that γ1 EQ mutation affects the BM assembly of laminins, which is not discernible at the level of conventional histology, thereby contributing to the phenotype of *Lamc1*^EQ/EQ^ embryos.

![BM formation in *Lamc1*^EQ/EQ^ zygotes.\
**(A--H)** Whole-mount immunostaining of WT (A, C, E, G) and *Lamc1*^*EQ*/*EQ*^ (B, D, F, H) blastocysts of E4.0 (A--D) and E4.3 (E--H) embryos. The asterisks indicate primitive endoderm cells. **(I, J)** Whole-mount immunostaining of E3.5 *Lamc1*^*EQ*/+^ (I) and *Lamc1*^*EQ*/*EQ*^ (J) blastocysts cultured ex vivo for 48 h. Magenta, laminin; green, perlecan (A, B, E, F, I, J) or integrin α6 (C, D, G, H); blue, nuclei. Bars, 50 μm. The genotypes of the preimplantation embryos were determined by genomic PCR. **(K, L)** In situ binding of integrin α7x2β1 (green) to E5.5 embryonic sections. The RM was counterstained with an anti-laminin-α1 mAb (magenta). Blue, nuclei. **(M, N)** Immunofluorescence staining for laminin-α1 (cyan), Cdx2 (magenta), and Oct3 (green) in WT or *Lamc1*^*EQ*/+^ (M) and *Lamc1*^*EQ*/*EQ*^ (N) E5.5 sections. The dashed lines indicate the region where extraembryonic ectoderm cells are associated with the BM. The open arrowheads indicate extraembryonic ectoderm cells dissociated from the BM. **(O)** Immunofluorescence staining for laminin (cyan) and laminin-α5 (green) in *Lamc1*^*EQ*/*EQ*^ E5.5 sections. Blue, nuclei. The asterisks and open triangles indicate visceral endoderm cells and parietal endoderm cells, respectively. The arrowheads indicate the laminin-α5--positive epiblast BM. Bars, 50 μm. **(P)** Summary of the strategy for quantitative image analysis of RM length in the E5.5 egg cylinder. The RM length (double-headed arrow) was measured by image tracing. **(Q)** RM lengths measured in E5.5 *Lamc1*^*EQ*/*EQ*^ embryos and control WT or *Lamc1*^*EQ*/+^ embryos. Data represent means ± SD. \*\*\**P* \< 0.001, significant difference by Welch\'s *t* test. The effect size was 3.13 and the statistical power was 1.0. ExE, extraembryonic ectoderm; Epi, epiblast.](LSA-2018-00064_Fig3){#fig3}

Because no apparent abnormalities in morphology and laminin deposition were observed in the *Lamc1*^*EQ*/*EQ*^ blastocysts, we investigated the early postimplantation development at E5.5 by immunofluorescence ([Fig 3K--O](#fig3){ref-type="fig"}). Expression of Oct4 and Cdx2, markers for the epiblast and extraembryonic ectoderm, respectively, was detected in *Lamc1*^*EQ*/*EQ*^ embryos and in the control WT/*Lamc1*^*EQ*/+^ littermates ([Fig 3M and N](#fig3){ref-type="fig"}). Visceral endoderm and parietal endoderm cells were also observed in *Lamc1*^*EQ*/*EQ*^ sections ([Fig 3O](#fig3){ref-type="fig"}). Thus, both embryonic and extraembryonic cell fate decisions occurred in *Lamc1*^*EQ*/*EQ*^ embryos. RM, which was stained with an anti-laminin-α1 antibody, was formed in control WT and *Lamc1*^*EQ*/+^ heterozygotes at E5.5 ([Fig 3K](#fig3){ref-type="fig"}). RM was also formed in *Lamc1*^*EQ*/*EQ*^ homozygotes at E5.5 ([Fig 3L](#fig3){ref-type="fig"}), but showed severe disorganization by E7.5 ([Fig 2J and K](#fig2){ref-type="fig"}). These findings indicate that RM formation was not affected in *Lamc1*^*EQ*/*EQ*^ mice until at least E5.5. It was previously shown in vivo that RM formation requires α1-containing laminins and dystroglycan ([@bib43]; [@bib24]). However, the deficient RM formation observed in *Lamc1*^*EQ*/*EQ*^ mice was different from that in laminin-α1 or dystroglycan knockout mice because the RM was initially formed in *Lamc1*^*EQ*/*EQ*^ mice.

γ1C-Glu--dependent integrin binding is indispensable for postimplantation development of extraembryonic tissues {#s6}
---------------------------------------------------------------------------------------------------------------

Although cell differentiation and BM formation appeared unaffected at E5.5, *Lamc1*^*EQ*/*EQ*^ embryos were smaller than control WT/*Lamc1*^*EQ*/+^ embryos ([Fig 3M and N](#fig3){ref-type="fig"}) and exhibited poor development of extraembryonic tissues. The parietal yolk sac in *Lamc1*^*EQ*/*EQ*^ embryos also appeared smaller than that in WT/*Lamc1*^*EQ*/+^ embryos ([Fig 3M and N](#fig3){ref-type="fig"}). Therefore, we investigated the development of the parietal yolk sac by measuring the RM length on sections by quantitative image analysis ([Fig 3P and Q](#fig3){ref-type="fig"}). After implantation at E5.5, the parietal yolk sac in WT and *Lamc1*^*EQ*/+^ zygotes grew expansively and the RM length reached 452 ± 83 μm when measured on sections. By contrast, the RM length in *Lamc1*^*EQ*/*EQ*^ homozygotes was 217 ± 41 μm at E5.5, being significantly smaller than that in control embryos. These findings clearly showed that the expansive growth of the parietal yolk sac was defective in *Lamc1*^*EQ*/*EQ*^ homozygotes. Interestingly, the extraembryonic ectoderm was dissociated from its BM in *Lamc1*^*EQ*/*EQ*^ E5.5 zygotes ([Fig 3N](#fig3){ref-type="fig"}), whereas that in the control WT/*Lamc1*^*EQ*/+^ zygotes was tightly associated with the BM ([Fig 3M](#fig3){ref-type="fig"}). The embryonic part of *Lamc1*^*EQ*/*EQ*^ embryos was not critically affected, as the epiblast and visceral endoderm remained associated with their laminin-α5--positive BMs ([Fig 3O](#fig3){ref-type="fig"}). These results indicated that postimplantation development of extraembryonic tissues was critically dependent on laminin--integrin interactions through γ1C-Glu. No single α3, α6, or α7 integrin knockout mice were reported to exhibit early postimplantation defects ([@bib7]; [@bib20]; [@bib5]). Because integrin α3 and α6 are dispensable for early postimplantation development, as shown by α3, α6 double-knockout mice ([@bib3]) early postimplantation development is probably secured by cooperative functioning of α7 integrin with α3 and/or α6 integrins. It is, therefore, likely that integrin α7 functions cooperatively with α3 and/or α6 integrins in extraembryonic tissues because integrin α7 is expressed in the trophectoderm-derived extraembryonic tissues ([@bib19]).

Conditional γ1 EQ knock-in mice as a tool for investigating the roles of laminin--integrin interactions in adult tissues {#s7}
------------------------------------------------------------------------------------------------------------------------

The above results clearly showed that the *Lamc1*^*EQ*^ knock-in allele is a valuable tool for investigating the roles of laminin--integrin interactions in vivo, although homozygotes die at the early postimplantation stage. Based on these results, we tried to develop a conditional knock-in mouse strain in which γ1C-Glu--dependent integrin binding can be ablated on demand. By homologous recombination in ES cells, we generated another *Lamc1* mutant allele, *Lamc1*^*cEQ*^, in which exon 28 was floxed and an additional EQ-mutated exon 28 was located in its 3′ downstream ([Fig 4A and B](#fig4){ref-type="fig"}). *Lamc1*^*cEQ*/*cEQ*^ homozygous mice were obtained according to the expected Mendelian ratio ([Fig 4C](#fig4){ref-type="fig"}) and appeared healthy and fertile.

![Generation of γ1 EQ conditional knock-in mice.\
**(A)** Schematic representation of the generation of *Lamc1*^*cEQ*^. The open boxes represent exons. The protein coding sequences are indicated in gray. The targeting construct was designed to replace WT exon 28 encoding Glu at residue 1,605 with a floxed exon 28 followed by a mutated exon 28 encoding Gln at residue 1,605. The probes used for Southern blotting are indicated by bold lines. **(B)** Southern blot analyses of genomic DNA from WT, *Lamc1*^*cEQ(neo)*/+^, and *Lamc1*^*cEQ*/+^ offspring after digestion with SexAI and PacI. The detection of 9.0 and 7.4 kbp fragments with probe 1 and probe 2, respectively, in the *Lamc1*^*cEQ(neo)*/+^ lanes indicates occurrence of the expected homologous recombination. The detection of a 7.4 kbp fragment with probe 1 in the *Lamc1*^*cEQ*/+^ lane indicates that the neomycin-resistance gene has been removed from the *Lamc1*^*cEQ(neo)*^ allele by the Cre-loxP system. **(C)** Genotypes of offspring obtained from *Lamc1*^*cEQ*/+^ intercrosses. **(D--I)** Histochemical analyses of *Lamc1*^*cEQ*/*cEQ*^ (D--F) and *Tie2-cre*;*Lamc1*^*cEQ*/*cEQ*^ (G--I) retinas. **(D, G)** In situ binding of recombinant integrin α3β1 (magenta) to frozen retinal sections. **(E, H)** Counterstaining of vascular BM with an anti--laminin-α5 antibody (green). Merged images with nuclear staining (blue) are also shown (F and I). Retinal vasculatures are indicated by filled (*Lamc1*^*cEQ*/*cEQ*^) and open (*Tie2-cre*;*Lamc1*^*cEQ*/*cEQ*^) arrowheads. Bars, 50 μm. **(J)** Genotypes of offspring obtained from mating between *Lamc1*^cEQ/+^ female and *Tie2-cre*;*Lamc1*^*cEQ*/+^ male mice. Only *Lamc1*^*cEQ*/*cEQ*^ and *Tie2-cre*;*Lamc1*^*cEQ*/*cEQ*^ mice are shown. S, SexAI restriction site; P, PacI restriction site; TK, thymidine kinase gene.](LSA-2018-00064_Fig4){#fig4}

Because the γ1 EQ knock-in mice showed embryonic lethality at the early developmental stage ([Fig 2C](#fig2){ref-type="fig"}), we determined whether tissue-specific ablation of γ1C-Glu--dependent laminin--integrin interactions is available while preventing embryonic lethality. We introduced the *Tie2-cre* transgene ([@bib16]), expressing Cre recombinase in an endothelial cell-specific manner, into the *Lamc1*^*cEQ*/*cEQ*^ genetic background, and examined whether integrin binding to laminins was ablated in blood vessels. When adult retinal sections were probed with recombinant integrin α3β1, recombinant integrin binding to blood vessel BMs was observed in control *Lamc1*^*cEQ*/*cEQ*^ mice ([Fig 4D--F](#fig4){ref-type="fig"}), but not in *Tie2-cre*;*Lamc1*^*cEQ*/*cEQ*^ mice ([Fig 4G--I](#fig4){ref-type="fig"}), consistent with blood vessel--specific introduction of the γ1 EQ mutation. As *Tie2-cre;Lamc1*^*cEQ*/*cEQ*^ mice were obtained according to the expected Mendelian ratio ([Fig 4J](#fig4){ref-type="fig"}), conditional ablation of γ1C-Glu--dependent laminin--integrin binding in vivo was shown to be feasible.

Here, we have revealed the significance of γ1C-Glu in the interactions of laminins with α3, α6, and α7 integrins by in vitro binding assays and by generating γ1 EQ knock-in mice. We have further developed a conditional γ1 EQ knock-in system in mice. Although laminin--integrin interactions have been extensively studied by in vitro analyses at the molecular and/or cellular levels, it has been difficult to verify the in vitro results in vivo. Our conditional γ1 EQ knock-in system in mice will be a valuable tool for investigating the roles of laminin--integrin interactions in various physiological and pathological situations in vivo.

Materials and Methods {#s8}
=====================

Antibodies and reagents {#s9}
-----------------------

Rat monoclonal antibodies (mAbs) against mouse laminin α1 (5B7-H1) and α5 (M5N8-C8) were produced as described ([@bib23]). Mouse mAbs against human laminin α1 (5A3), α5 (15H5), β1 (DG10), and γ1 (C12SW) were produced as described previously ([@bib15]; [@bib12]). Mouse mAbs against human laminin β1 were purchased from Enzo Life Sciences. Rabbit polyclonal antibody (pAb) against Velcro (ACID/BASE coiled-coil) peptides was produced as described ([@bib38]). Mouse anti-FLAG mAb, rabbit anti-laminin pAb, and BSA were obtained from Sigma-Aldrich; rat anti-perlecan mAb was purchased from Merck Millipore; rat anti-mouse integrin-α6 mAb (GoH3) was from BD Biosciences; mouse anti-Cdx2 mAb was from Biocare; rabbit anti-Oct4 pAb was from Santa Cruz Biotechnology; HRP-conjugated donkey anti-mouse IgG and Cy3-conjugated anti-rat IgG were from Jackson ImmunoResearch; Alexa 488-conjugated goat anti-rabbit IgG, Alexa 546-conjugated goat anti-rat IgG, Alexa 405-conjugated goat anti-rabbit IgG, Alexa 488-conjugated goat anti-rat IgG, and Alexa 546-conjugated goat anti-mouse IgG were from Invitrogen; HRP-conjugated streptavidin was from Thermo Fisher Scientific. Rat anti-cytokeratin-8 mAb (TROMA-I), developed by Philippe Brulet and Rolf Kemler, was obtained from the Developmental Studies Hybridoma Bank. The antibody dilutions used are shown in Table S1. Bovine type I and type IV collagens were obtained from Nippi Inc. Mouse laminin-111 was prepared from mouse Engelbreth-Holm-Swarm tumor as described previously ([@bib26]). Fibronectin was purified from human plasma by gelatin affinity chromatography as described previously ([@bib33]).

Table S1 List of antibodies used in this study.

Expression vectors {#s10}
------------------

Expression vectors for human laminin α1, α5, β1, and FLAG-tagged γ1 chains were prepared as described ([@bib8]; [@bib9], [@bib10], [@bib11]). The FLAG tag of laminin γ1 was located just after the N-terminal signal peptide cleavage site to facilitate purification of recombinant laminins. Expression vectors for the extracellular domains of the human integrin α1, α2, α3, α6, α7x1, α7x2, and α9 subunits were constructed as described ([@bib26]; [@bib32]; [@bib13]). Expression vectors for the extracellular domains of the human integrin αv, β1, β3, and β4 subunits were kindly provided by Dr. Junichi Takagi (Institute for Protein Research, Osaka University) ([@bib38], [@bib37], [@bib39]). An expression vector for the extracellular domains of human integrin α5 was constructed in a similar manner to those of other integrin α subunits ([@bib26]; [@bib32]; [@bib13]). An expression vector for the extracellular domain of human integrin β5 was prepared using a cDNA amplified from RNA extracted from T98G human glioblastoma cells. Expression vectors for recombinant human vitronectin with an N-terminal FLAG tag and the C-terminal fragment of mouse polydom were prepared as described ([@bib32]; [@bib27]).

Expression and purification of recombinant proteins {#s11}
---------------------------------------------------

Recombinant human laminin-111, laminin-511, and their EQ mutants were produced using a FreeStyle 293 Expression System (Thermo Fisher Scientific) as described ([@bib9]). The conditioned media were passed over ANTI-FLAG M2 Affinity Gel (Sigma-Aldrich). After washing with 20 mM Tris-buffered saline without divalent cations (TBS), bound proteins were eluted with 100 μg/ml FLAG peptide (Sigma-Aldrich) and dialyzed against TBS. Purified proteins were verified by 4% SDS--PAGE under reducing conditions ([Fig S1](#figS1){ref-type="fig"}). Other recombinant proteins (integrin α1β1, α2β1, α3β1, α6β1, α7x1β1, α7x2β1, α9β1, αvβ3, αvβ5, and α5β1, and vitronectin and C-terminal fragment of polydom) were produced using the FreeStyle 293 Expression System and purified on ANTI-FLAG M2 Affinity Gel as described above. Protein concentrations were determined with a BCA protein assay kit (Thermo Fisher Scientific) using BSA as a standard.

Laminin secretion assay {#s12}
-----------------------

Recombinant human laminin-111, laminin-511, and their EQ mutants were produced using the FreeStyle 293 Expression System as described above. Conditioned media were recovered at 3 d after transfection and applied to SDS--PAGE and subsequent Western blot analyses.

Western blotting {#s13}
----------------

E7.5 embryos were lysed in 20 μl of SDS--PAGE sample buffer under nonreducing conditions. Purified laminins were prepared as samples for SDS--PAGE under reducing conditions. Conditioned media of human 293 cells were mixed with equal amounts of 2× SDS--PAGE sample buffer under nonreducing conditions. Proteins were separated by 4% SDS--PAGE and transferred onto nitrocellulose membranes. The membranes were immunoblotted with the indicated primary Abs and goat anti-rabbit or anti-mouse IgG secondary antibodies conjugated with HRP (Jackson ImmunoResearch Laboratories). The bound primary antibody was visualized with an Amersham ECL Prime Western blotting detection reagent kit (GE Healthcare).

Integrin binding assays {#s14}
-----------------------

Solid-phase assays for binding of integrins to laminins, collagens, vitronectin, and polydom were carried out as described ([@bib42]). Briefly, 96-well microtiter plates were coated with recombinant proteins (laminins, vitronectin, and polydom, 5 nM; collagens, 10 μg/ml) overnight at 4°C, blocked with 3% BSA for 1 h at room temperature, and incubated with 30 nM integrins for 3 h at room temperature in the presence of 1 mM Mn^2+^. Bound integrins were detected after sequential incubations with biotinylated rabbit anti-Velcro pAb and HRP-conjugated streptavidin. The amounts of recombinant laminins, vitronectin, and polydom adsorbed on the plates were quantified by enzyme-linked immunosorbent assays using an anti-FLAG M2 mAb to confirm equality of the adsorbed proteins.

Mice {#s15}
----

The B6.Cg-Tg(CAG-cre)CZ-MO2Osb mouse strain expressing Cre-recombinase under the CAG promoter (BRC No. 01828) was provided by the RIKEN BioResource Center with support from the National BioResource Project of the Ministry of Education, Culture, Sports, Science and Technology, Japan. The B6-Tg(CAG-FLPe)36 mouse strain expressing Flp-recombinase under the CAG promoter (BRC No. 01834) ([@bib14]) was also provided by RIKEN BioResource Center with support from the National BioResource Project of the Ministry of Education, Culture, Sports, Science and Technology, Japan. The B6.Cg-Tg(Tek-cre)1Ywa/J (*Tie2-cre*) mouse strain expressing Cre-recombinase under the Tek (Tie2) promoter ([@bib16]) was provided by Jackson Laboratory.

To generate *Lamc1*^*EQ*^ knock-in mice, a knock-in vector was constructed to include the 2-kb upstream *Lamc1* genomic sequence, a neomycin-resistance gene sandwiched by loxP sequences, the 5-kb downstream *Lamc1* genomic sequence, and a thymidine kinase gene, as shown schematically in [Fig 2A](#fig2){ref-type="fig"}. To introduce the γ1 EQ mutation, the 5-kb genomic sequence was point-mutated by overlap-extension PCR. The knock-in vector was introduced into strain 129 mouse ES cells. The resulting targeted clones were verified by PCR and Southern blotting and injected into C57Bl/6 blastocysts to obtain chimeric mice. Male chimeric mice that transmitted the mutated *Lamc1* gene through the germline were crossed with C57Bl/6 female mice (Japan SLC) to generate *Lamc1*^*EQ(Neo)*^ mice. The *Lamc1*^*EQ(Neo)*/+^ heterozygotes were crossed with B6.Cg-Tg(CAG-cre)CZ-MO2Osb mice to obtain *Lamc1*^*EQ*/+^ heterozygotes, in which the neomycin-resistance gene was removed. The *Lamc1*^*EQ*/+^ heterozygotes were crossed to obtain *Lamc1*^*EQ*/*EQ*^ homozygotes and WT littermates. E0.5 was defined as noon on the day of plug detection.

To generate *Lamc1*^*cEQ*^ mice, a knock-in vector was constructed as follows. The vector included the 2-kb upstream *Lamc1* genomic sequence, a neomycin-resistance gene sandwiched by loxP sequences, the 5-kb downstream *Lamc1* genomic sequence, and a thymidine kinase gene, as shown schematically in [Fig 4A](#fig4){ref-type="fig"}. To introduce the γ1 EQ mutation, the 5-kb genomic sequence was point-mutated by overlap-extension PCR. The knock-in vector was introduced into strain 129 mouse ES cells. The resulting targeted clones were verified by PCR and Southern blotting, and injected into C57Bl/6 blastocysts to obtain chimeric mice. Male chimeric mice that transmitted the mutated *Lamc1* gene through the germline were crossed with C57Bl/6 female mice to generate *Lamc1*^*cEQ(Neo)*^ mice. The resulting *Lamc1*^*cEQ(Neo)*/+^ heterozygotes were crossed with B6-Tg(CAG-FLPe)36 mice to obtain *Lamc1*^*cEQ*/+^ heterozygotes in which the neomycin-resistance gene was removed. *Lamc1*^*cEQ*/+^ heterozygotes were crossed to obtain *Lamc1*^*cEQ*/*cEQ*^ homozygotes and WT littermates. *Lamc1*^*cEQ*/+^ heterozygotes were mated with *Tie2-cre* mice to obtain *Lamc1*^*cEQ*/+^;*Tie2-cre* mice. *Lamc1*^*cEQ*/+^;*Tie2-cre* male mice were mated with *Lamc1*^*cEQ*/+^ mice to obtain *Lamc1*^*cEQ*/*cEQ*^;*Tie2-cre* and control *Lamc1*^*cEQ*/*cEQ*^ littermates.

The mice were kept in a specific pathogen-free environment under stable conditions of temperature and light (lights ON at 08:00 and OFF at 20:00). All mouse experiments were performed in compliance with our institutional guidelines and were approved by the Animal Care Committee of Osaka University.

Ex vivo blastocyst culture {#s16}
--------------------------

E3.5 blastocysts were flushed from the uterus with flushing-holding medium ([@bib21]), washed with potassium simplex optimization medium ([@bib21]), and cultured in a hanging drop of potassium simplex optimization medium at 37°C for 48 h under 5% CO~2~.

Genotyping {#s17}
----------

Genomic DNAs were extracted with DirectPCR Lysis Reagent (Viagen Biotech) at 55°C overnight and then heat-denatured at 95°C for 10 min.

The genotypes of *Lamc1*^*EQ*^ postnatal mice and whole-mount embryos were determined by genomic PCR using the primer pair 5′-AAGCAGGAGGCAGCCATCATGGACT-3′ and 5′-GGAAGATGCCGTGACTTCAGGCAAA-3′. WT DNA and *Lamc1*^EQ^ DNA both gave PCR products of approximately 400 bp. The PCR products were digested with TaqI and separated by 1.8% agarose gel electrophoresis. Although the PCR product derived from the WT allele was digested into bands of 280 and 120 bp, the PCR product derived from the *Lamc1*^*EQ*^ allele remained undigested because the γ1 EQ mutation abolished the TaqI site.

Because it is difficult to isolate embryonic tissues without contamination by surrounding maternal tissues, the genotypes of sectioned embryos were determined by their integrin-binding activity in situ ([@bib17]). For sectioned E5.5--E7.5 embryos, the genotypes were determined by in situ binding of recombinant integrin α7x2β1. Embryos that showed integrin α7x2β1 binding to anti-laminin immunoreactive sites were genotyped as WT or *Lamc1*^*EQ*/+^, whereas those that did not show α7x2β1 binding were genotyped as *Lamc1*^*EQ*/*EQ*^. As *Lamc1*^*EQ*/+^ mice appeared normal, we did not distinguish *Lamc1*^*EQ*/+^ from WT after genotyping by in situ integrin binding and their genotypes are presented as WT or *Lamc1*^*EQ*/+^ in the relevant figures.

The genotypes of *Lamc1*^*cEQ*^ mice were determined by genomic PCR using the primer pair 5′-TTACCAAGTCACCTTCTTCAGCATAAGCGA-3′ and 5′-GTACATGCGTGTCTGCATGAATGCCATA-3′. The sizes of the PCR products from the WT and *Lamc1*^*cEQ*^ alleles were 234 and 423 bp, respectively.

The genotypes of the *Tie2-cre* transgene were determined by genomic PCR using the primer pair 5′-GTTTCACTGGTTATGCGGCGG-3′ and 5′-TTCCAGGGCGCGAGTTGATAG-3′. The size of the PCR product was 450 bp.

In situ integrin binding {#s18}
------------------------

In situ integrin binding was performed as described ([@bib18], [@bib17]). Frozen sections of mouse embryos were blocked with blocking buffer (3% BSA, 25 mM Tris--HCl pH 7.4, 100 mM NaCl, and 1 mM MnCl~2~) for 30 min at room temperature, and then incubated with 3 μg/ml of recombinant integrin α7x2β1 and rat anti-laminin-α1 mAb (5B7-H1) in blocking buffer at 4°C overnight. The sections were washed three times with wash buffer (25 mM Tris--HCl pH 7.4, 100 mM NaCl, and 1 mM MnCl~2~) for 10 min at room temperature, and incubated with 0.5 μg/ml of rabbit anti-Velcro pAb in blocking buffer at room temperature for 2 h. After washing with wash buffer, the sections were incubated with Alexa 488-conjugated goat anti-rabbit IgG and Cy3-conjugated anti-rat IgG. The nuclei were stained with Hoechst 33342. After washing with wash buffer, the sections were mounted in PermaFluor (Thermo Scientific Shandon) and visualized with an LSM510 laser confocal microscope (Carl Zeiss).

Immunofluorescence {#s19}
------------------

Whole-mount immunofluorescence of blastocysts was performed as follows: Blastocysts were fixed in 4% paraformaldehyde in PBS at 4°C for 10 min. The fixed blastocysts were washed with PBS, permeabilized with 0.1% Triton X-100 in PBS at 4°C for 10 min, and incubated with a rabbit anti-laminin pAb and rat anti-perlecan mAb or rat anti-mouse integrin-α6 mAb (GoH3) diluted in 0.1% Tween-20/PBS (TPBS) at 4°C overnight. The embryos were then washed three times with TPBS for 10 min, and incubated with Alexa 546-conjugated goat anti-rabbit IgG and Alexa 488-conjugated goat anti-rat IgG. The nuclei were stained with Hoechst 33342 for 2 h. After three washes with TPBS for 10 min, the blastocysts were placed in a small drop of PBS covered with mineral oil on a coverslip, and visualized under the LSM510 confocal microscope.

Immunofluorescence of sectioned tissues was also performed. Frozen sections of mouse embryos were fixed in 4% paraformaldehyde in PBS at 4°C for 10 min, blocked with 3% BSA/TPBS at 4°C for 30 min, and incubated at 4°C overnight with the following antibodies diluted in 3% BSA/TPBS: mixture of rabbit anti-laminin pAb and rat anti--cytokeratin-8 mAb (TROMA-I); mixture of rat anti--laminin-α1 mAb, mouse anti-Cdx2 mAb, and rabbit anti-Oct4 pAb; or mixture of rabbit anti-laminin pAb and rat anti--laminin-α5 mAb (M5N8-C8). The sections were washed three times with TPBS for 10 min, and incubated at 4°C for 2 h with the following secondary antibodies: Alexa 488-conjugated goat anti-rabbit IgG and Alexa 546-conjugated goat anti-rat IgG; or Alexa 405-conjugated goat anti-rabbit IgG, Alexa 488-conjugated goat anti-rat IgG, and Alexa 546-conjugated goat anti-mouse IgG. The nuclei were stained with Hoechst 33342 if necessary. After three washes with TPBS for 10 min, the sections were mounted in PermaFluor and visualized using the LSM510 laser confocal microscope.

Frozen sections of 8-wk-old mouse retina were air-dried for 30 min at room temperature, fixed with cold acetone at −30°C for 15 min, washed with TBS, blocked with blocking buffer (1% BSA, 25 mM Tris--HCl pH 7.4, 100 mM NaCl, and 1 mM MnCl~2~) for 30 min at room temperature, and incubated with 3 μg/ml of recombinant integrins and specified antibodies in blocking buffer at 4°C overnight. The sections were washed three times with wash buffer (25 mM Tris--HCl pH 7.4, 100 mM NaCl, and 1 mM MnCl~2~) for 10 min at room temperature, and incubated with 0.5 μg/ml of rabbit anti-Velcro pAb and anti--laminin-α5 mAb in blocking buffer at room temperature for 2 h. After washing with wash buffer, the sections were incubated with Alexa 488-conjugated goat anti-rabbit IgG and Alexa 546-conjugated anti-rat IgG. The nuclei were stained with Hoechst 33342. After washing with wash buffer, the sections were mounted in PermaFluor and visualized using the LSM510 laser confocal microscope.

The LSM510 laser confocal microscope was equipped with LD-Achroplan (20×, NA 0.4) and Plan-Neofluar (10×, NA 0.3; 40×, NA 0.75) objective lenses at room temperature. The imaging medium was air. The LSM510 PASCAL software (Carl Zeiss) was used for image collection. Each set of stained samples was processed under identical gain and laser power settings. Each set of obtained images was processed under identical brightness and contrast settings, which were adjusted by the LSM image browser (Carl Zeiss) and ImageJ software ([@bib1]) for clear visualization of BMs. At least four pairs of sections for mutant mice and their control littermates were examined, and similar results were obtained.

Image analysis {#s20}
--------------

The length of the RM was measured on anti-laminin immunofluorescence-stained images of E5.5 egg cylinders using ImageJ software (see also [Fig 3P](#fig3){ref-type="fig"}).

Statistical analysis {#s21}
--------------------

A normal distribution of data was confirmed by normal quantile--quantile plot analysis. Effect size, post hoc analyses for actual statistical power (1−β), and a priori analyses for required sample sizes under given statistical parameters for two-mean analyses were determined by G\*Power version 3.1.9.2 ([@bib4]). Statistical significance was determined by a two-tailed Welch\'s *t* test using Microsoft Excel for Mac 2011. A value of *P* \< 0.05 was considered to indicate a statistically significant difference. *P*-values are only shown in figures where the actual statistical power was ≥0.8.
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